Argus Research analyst Jasper Hellweg maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report) yesterday. The company’s shares ...

Teva Pharmaceutical (NYSE:TEVA) shares snapped six straight sessions of losses, as the stock closed 0.88% higher at $17.21 on Wednesday. The company lost over 20% in the preceding six sessions.

Looking ahead, revenue is forecast to grow 3.6% p.a. on average during the next 3 years, compared to a 8.6% growth forecast for the Pharmaceuticals industry in the US.

2025 Free Cash Flow Guidance: $1.6 billion to $1.9 billion. Teva Pharmaceutical Industries Ltd (NYSE:TEVA) reported a 9% increase in revenue for 2024, reaching $16.5 billion, driven by strong ...

Investors with a lot of money to spend have taken a bullish stance on Teva Pharmaceutical Indus TEVA. And retail traders should know. We noticed this today when the trades showed up on publicly ...

Axsome Therapeutics has resolved the patent infringement lawsuit that it filed against Teva Pharmaceutical Industries after the generics powerhouse sought FDA approval for a copycat to Axsome's ...

Teva Pharmaceuticals Industries Ltd TEVA is the world's largest generic drug maker, with over 500 generic and biosimilar treatments in its broad portfolio. The medical sector giant also has a line ...

Considering Teva’s extended-release version of Austedo won a key approval in 2023, ramped-up competition in 2025 is something the team at Evercore ISI had anticipated. Even so, this year’s fir ...

Teva Pharmaceutical Industries Limited has a 12-month low of $11.83 and a 12-month high of $22.80. The stock has a market capitalization of $19.07 billion, a PE ratio of -11.61, a price-to ...